These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 20378007)

  • 1. Soluble CD30: a biomarker for evaluating the clinical risk versus benefit of IFNbeta1A treatment in multiple sclerosis patients.
    Contasta I; Totaro R; Berghella AM; Pellegrini P; Del Beato T; Carolei A; Adorno D
    Int J Immunopathol Pharmacol; 2010; 23(1):213-26. PubMed ID: 20378007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD30 antigen and multiple sclerosis: CD30, an important costimulatory molecule and marker of a regulatory subpopulation of dendritic cells, is involved in the maintenance of the physiological balance between TH1/TH2 immune responses and tolerance. The role of IFNbeta-1a in the treatment of multiple sclerosis.
    Pellegrini P; Totaro R; Contasta I; Berghella AM; Carolei A; Adorno D
    Neuroimmunomodulation; 2005; 12(4):220-34. PubMed ID: 15990453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD30 antigen: not a physiological marker for TH2 cells but an important costimulator molecule in the regulation of the balance between TH1/TH2 response.
    Pellegrini P; Berghella AM; Contasta I; Adorno D
    Transpl Immunol; 2003; 12(1):49-61. PubMed ID: 14551032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological study of IFNbeta-1a-treated and untreated multiple sclerosis patients: clarifying IFNbeta mechanisms and establishing specific dendritic cell immunotherapy.
    Berghella AM; Totaro R; Pellegrini P; Contasta I; Russo T; Carolei A; Adorno D
    Neuroimmunomodulation; 2005; 12(1):29-44. PubMed ID: 15756051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Passage from normal mucosa to adenoma and colon cancer: alteration of normal sCD30 mechanisms regulating TH1/TH2 cell functions.
    Contasta I; Berghella AM; Pellegrini P; Adorno D
    Cancer Biother Radiopharm; 2003 Aug; 18(4):549-57. PubMed ID: 14503949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A gender-related action of IFNbeta-therapy was found in multiple sclerosis.
    Contasta I; Totaro R; Pellegrini P; Del Beato T; Carolei A; Berghella AM
    J Transl Med; 2012 Nov; 10():223. PubMed ID: 23148845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple sclerosis: expression of CD1a and production of IL-12p70 and IFN-gamma by blood mononuclear cells in patients on combination therapy with IFN-beta and glatiramer acetate compared to monotherapy with IFN-beta.
    Hussien Y; Sanna A; Söderström M; Link H; Huang YM
    Mult Scler; 2004 Feb; 10(1):16-25. PubMed ID: 14760948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short communication: decreasing soluble CD30 and increasing IFN-gamma plasma levels are indicators of effective highly active antiretroviral therapy.
    Sadeghi M; Süsal C; Daniel V; Naujokat C; Zimmermann R; Huth-Kühne A; Opelz G
    AIDS Res Hum Retroviruses; 2007 Jul; 23(7):886-90. PubMed ID: 17678471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Redox, immune and genetic biomarker system for personalized treatments in colorectal cancer.
    Berghella AM; Aureli A; Canossi A; Beato TD; Colanardi A; Pellegrini P
    World J Gastrointest Oncol; 2019 Feb; 11(2):117-138. PubMed ID: 30788039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Release of soluble CD30 after allogeneic stimulation is mediated by memory T cells and regulated by IFN-γ and IL-2.
    Velásquez SY; García LF; Opelz G; Alvarez CM; Süsal C
    Transplantation; 2013 Jul; 96(2):154-61. PubMed ID: 23857000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased bone marrow (BM) plasma level of soluble CD30 and correlations with BM plasma level of interferon (IFN)-γ, CD4/CD8 T-cell ratio and disease severity in aplastic anemia.
    Wu Q; Zhang J; Shi J; Ge M; Li X; Shao Y; Yao J; Zheng Y
    PLoS One; 2014; 9(11):e110787. PubMed ID: 25383872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro soluble CD30 levels in patients with chronic stable coronary artery disease.
    Mahmoudi MJ; Hedayat M; Rezaei N; Saboor-Yaraghi AA; Mahmoudi M
    Iran J Allergy Asthma Immunol; 2011 Dec; 10(4):237-42. PubMed ID: 22184265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
    Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
    J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-beta inhibits Th1 responses at the dendritic cell level. Relevance to multiple sclerosis.
    Bartholomé EJ; Willems F; Crusiaux A; Thielemans K; Schandené L; Goldman M
    Acta Neurol Belg; 1999 Mar; 99(1):44-52. PubMed ID: 10218092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma soluble CD30 level correlates negatively with age in children.
    Chen JY; Fu LS; Chu JJ; Chen HC; Chi CS
    J Microbiol Immunol Infect; 2007 Apr; 40(2):168-72. PubMed ID: 17446967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-gamma, interleukin-4 and transforming growth factor-beta mRNA expression in multiple sclerosis and myasthenia gravis.
    Link J
    Acta Neurol Scand Suppl; 1994; 158():1-58. PubMed ID: 7732782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD30 cell expression and abnormal soluble CD30 serum accumulation in Omenn's syndrome: evidence for a T helper 2-mediated condition.
    Chilosi M; Facchetti F; Notarangelo LD; Romagnani S; Del Prete G; Almerigogna F; De Carli M; Pizzolo G
    Eur J Immunol; 1996 Feb; 26(2):329-34. PubMed ID: 8617299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble CD30 levels in plasma and cerebrospinal fluid in multiple sclerosis, HIV infection and other nervous system diseases.
    Navikas V; Martin C; Matusevicius D; Söderström M; Fredrikson S; Link H
    Acta Neurol Scand; 1997 Feb; 95(2):99-102. PubMed ID: 9059729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of the soluble CD30 serum level in colorectal cancer: a possible marker for a patient subset which could benefit from IL-2 biotherapy.
    Dle Beato T; Berghella AM; Pellegrini P; Domenico A; Casciani CU
    Cancer Biother Radiopharm; 1997 Oct; 12(5):297-304. PubMed ID: 10851480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating soluble-CD30 (sCD30) in patients with HCV-related chronic hepatitis and in patients with alcoholic liver disease.
    De Lazzari F; Ravagnan P; Tenderini M; Vicarioto MA; Galliani EA; Lorenzoni U; Popovic A; Floreani A
    Hepatogastroenterology; 2002; 49(43):231-4. PubMed ID: 11941962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.